News Press Contact: Kirsten Mabry | (617) 495-4157

Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.

Drawing inspiration from how organisms regulate temperature using liquids—such as perspiration and blood vessel constriction—researchers at SEAS are developing a liquid-based screen that adheres to windows and controls how much heat and light pass through.

BioMed X and Harvard launched a pilot initiative under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements.

Sam Liss will become the next leader of OTD as the University’s chief technology development officer and associate provost.